[Small-molecule tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR)].

Abstract excerpt

Five years have passed since the activating mutation of the epidermal growth factor receptor (EGFR) gene was discovered. Patients with lung cancer harboring EGFR mutation respond remarkably well to small molecules, such as gefitinib or erlotinib, that specifically inhibit tyrosine kinase of the EGFR. Furthermore, recent evidence leads strong support to the idea that EGFR-tyrosine kinase inhibitors prolong...

Topics

• ErbB Receptors
• Female
• Genes, erbB-1
• Humans
• Lung Neoplasms
• Male
• Mutation
• Protein-Tyrosine Kinases